Living with Pulmonary Arterial Hypertension (PAH) affects not only patients but also the caregivers who support them, facing ...
Patients with systemic sclerosis who have lipodermatosclerosis vs those without lipodermatosclerosis have a higher rate of cardiac arrhythmia, heart failure, and pulmonary hypertension.
The oxygen-sensing protein HIF-1alpha may contribute to worsening pulmonary arterial hypertension (PAH) and is a possible ...
Treating PAH patient-derived blood vessel cells with calcitriol reduced vitamin D receptor deficiency and suppressed their ...
Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...
I hope that, in the long-term, our technology will improve patient outcomes for this disease. We can also use our technology ...
Keros Therapeutics said on Thursday it had paused giving patients higher doses of its high blood pressure treatment in a ...
Keros Therapeutics (NASDAQ:KROS) stock plunged 73% Thursday after the company said it has halted two arms of a Phase 2 ...
Keros’ stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure ...
Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the ...
Biopharmaceutical company Keros Therapeutics, Inc. (KROS) announced Thursday that it has voluntarily halted dosing in the 3.0 mg/kg ...
Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE ...